Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, has expanded its service offering for spray-drying of proteins for pulmonary delivery.
 
The new offering provides clinical and commercial manufacturing services at a kilogram scale from Lonza’s Bend (US) site, home to Lonza’s Center of Excellence for respiratory delivery.

Offering Spray Drying of Biologics

The administration of protein-based therapies to treat respiratory disease has historically been limited to intravenous or subcutaneous injections, which require frequent and costly administration and rely on patient compliance. The focused and local delivery method of a solid protein formulation to the lung offers a viable alternative that can also reduce dose and off-target exposure. Shelf-stable dry powder inhalers improve patient access worldwide by reducing reliance on cold chain logistics.
 
Kimberly Shepard, Director, Respiratory Delivery, Lonza, commented: “Pulmonary delivery of solid protein formulations using a dry powder inhaler is a growing trend among drug developers. Our new clinical offering further strengthens our world-leading spray-drying expertise and provides manufacturing capacity from early-phase to commercial supply. This expertise and capability enable our customers to bring innovative new medicines to patients with unmet medical needs.”

More Lonza News

Lonza recently signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, California from Roche for $1.2 billion.